Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan Proof-of-Concept Randomized Trial
Semaglutide is not a hormone replacement and should not replace prescribed HRT or other endocrine treatments
Jun 10, 2025, 08:00 ET Full data of Phase 3 REDEFINE 1 and 2 trial results will provide insights on the potential of CagriSema Semaglutide real-world data complements evidence from previous cardiometabolic and kidney outcomes trials Data on pipeline candidate amycretin to underscore Novo Nordisk's scientific efforts to continued innovation in obesity PLAINSBORO, N.J., June 10, 2025 /PRNewswire/ -- Novo Nordisk today announced that new data from its industry-leading cardiometabolic portfolio will be showcased at the upcoming American Diabetes Association (ADA) 85 th Scientific Sessions taking place in Chicago, June 20 23, 2025
2/4/2025 TARA LACHMAN It is working as they Say
Crystal structure of glutamate-1-semialdehyde aminomutase: an alpha2-dimeric vitamin B6-dependent enzyme with asymmetry in structure and active site reactivity
The standard recommendation is one 500 mcg capsule twice daily on an empty stomach